Skip to Main Content
Back to News

Abbott Laboratories Stock (ABT) Opinions on Q3 2025 Earnings Report

None

Recent chatter on X about Abbott Laboratories (ABT) has centered on the company’s third-quarter 2025 earnings report, which showed mixed results. Many users have pointed out the slight revenue miss, attributing it to weaker demand in diagnostics and nutritional segments, while others highlight the strength in medical device sales as a positive note. The stock’s subsequent dip has sparked debates about whether this presents a potential opportunity or signals deeper concerns.

Discussions also reflect on the company’s narrowed full-year guidance for 2025, with some expressing frustration over the lack of upside surprises in the numbers. A few voices on X remain optimistic, emphasizing the long-term growth potential in Abbott’s medtech portfolio despite short-term hiccups. The conversation continues to evolve as investors weigh the balance between temporary setbacks and sustained fundamentals.

Note: This discussion summary was generated from an AI condensation of post data.

Abbott Laboratories Congressional Stock Trading

Members of Congress have traded $ABT stock 8 times in the past 6 months. Of those trades, 3 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Abbott Laboratories Insider Trading Activity

ABT Insider Trades

Abbott Laboratories insiders have traded $ABT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:

  • PHILIP P BOUDREAU (EVP AND CFO) sold 5,550 shares for an estimated $746,758
  • SALLY E. BLOUNT sold 2,600 shares for an estimated $337,116

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Abbott Laboratories Hedge Fund Activity

We have seen 1,406 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,376 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Abbott Laboratories Government Contracts

We have seen $86,209,736 of award payments to $ABT over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Abbott Laboratories Analyst Ratings

Wall Street analysts have issued reports on $ABT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Evercore ISI Group issued a "Outperform" rating on 10/16/2025
  • RBC Capital issued a "Outperform" rating on 10/16/2025
  • Wells Fargo issued a "Overweight" rating on 10/16/2025
  • Raymond James issued a "Outperform" rating on 10/16/2025
  • BTIG issued a "Buy" rating on 10/15/2025
  • Benchmark issued a "Buy" rating on 10/10/2025
  • Jefferies issued a "Buy" rating on 07/18/2025

To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.

Abbott Laboratories Price Targets

Multiple analysts have issued price targets for $ABT recently. We have seen 9 analysts offer price targets for $ABT in the last 6 months, with a median target of $145.0.

Here are some recent targets:

  • Shagun Singh from RBC Capital set a target price of $147.0 on 10/16/2025
  • Jayson Bedford from Raymond James set a target price of $146.0 on 10/16/2025
  • Lawrence Biegelsen from Wells Fargo set a target price of $146.0 on 10/16/2025
  • Vijay Kumar from Evercore ISI Group set a target price of $142.0 on 10/16/2025
  • Marie Thibault from BTIG set a target price of $145.0 on 10/15/2025
  • Bruce Jackson from Benchmark set a target price of $145.0 on 10/10/2025
  • Anthony Petrone from Mizuho set a target price of $135.0 on 07/18/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles